Navigation Links
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
Date:3/4/2013

requent adverse events (AEs) in STARTVerso™ 4 were nausea (37%), fatigue (33%), diarrhea (27%), headache (23%), and weakness (22%). Serious AEs were reported in 32 patients (10%), including three deaths. To date, 18 patients have discontinued study participation due to AEs. The safety results of this study were comparable to those observed in HCV mono-infected treatment-naive patients in prior faldaprevir clinical studies. No patient on ART experienced a loss of HIV viral suppression during the study period.

In a separate oral presentation at CROI, investigators described the results from three open-label Phase 1 studies in healthy volunteers that evaluated the drug-drug interactions of faldaprevir with the common HIV medications darunavir/ritonavir, efavirenz, or tenofovir. In each of these studies, there was no clinically relevant effect of faldaprevir on the pharmacokinetics of any of the HIV medications studied. However, the respective effects of darunavir/ritonavir and efavirenz on faldaprevir informed the study design of STARTVerso™ 4. Patients already taking darunavir/ritonavir or efavirenz were enrolled into the 120mg and 240mg faldaprevir groups in STARTVerso™ 4, respectively.

These drug-drug interaction findings are part of a comprehensive program to evaluate potential drug interactions of faldaprevir with other medications commonly taken by the diverse patient populations infected with HCV. Most AEs in the drug-drug interaction studies were mild or moderate and all were resolved by the end of the trials. Four healthy volunteers discontinued trial participation due to AEs, including mild or moderate rash, mild elevation in hepatic enzyme levels, or moderate myalgia.

"The interim virologic response rates from STARTVerso™ 4 in HCV/HIV co-infected patients, combined with the drug-drug interaction results of faldaprevir with common HIV medications, are encouraging as we continue toward our goal of developing new HCV
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... in bone mineral density at the,lumbar spine and ... salmeterol inhalation powder) and salmeterol, - Study ... in patients,with COPD, PHILADELPHIA, Oct. 29 ... three-year study of patients with,Chronic Obstructive Pulmonary Disease ...
... Cryoablation ... Treatment Technology, PLEASANTON, ... (ACOSOG) which just initiated a National Cancer,Institute (NCI) funded clinical ... Therapy in the Treatment of Invasive Breast,Carcinoma," has selected the ...
Cached Medicine Technology:Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 2Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 3NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3
(Date:12/24/2014)... For chic ladies, new fashionable outfits are necessary ... their Holiday Wish List, Angeldress.co.uk has chosen some ... accent ladies’ holiday wardrobe by launching a promotion on its ... the discount of 80% off, like a cheap suit. , ... company’s chic wedding dresses are among the hottest items in ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... regards to the various market dynamics such as the ... assisted arthroscopy, the wait time for U.S. sports medicine, ... medicine market, and the challenges faced by the market. ... http://www.researchmoz.us/global-sports-medicine-market-report-2014-edition-report.html , The report also provides an overview ...
(Date:12/24/2014)... Plantation, FL (PRWEB) December 24, 2014 ... permanent solution for a tooth replacement. They offer the ... boast several advantages over other forms of tooth replacement. ... not rely on the adjacent teeth for support, and ... many people have been told that they are not ...
(Date:12/24/2014)... Viejo, California (PRWEB) December 24, 2014 ... release of the ProDenoise from Pixel Film Studios. , “The ... noise or grain in their footage,” said Christina Austin, CEO ... have in any Final Cut Pro X editors toolbox.” , ... film noise or grain in their footage with ProDenoise from ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... good news about the experimental Ebola vaccine that U.S. officials ... shows a precursor of that vaccine produced a safe ... of the vaccine, when given to more than 100 Ugandans ... white blood cells that could potentially protect a person against ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
... Amanda Gardner HealthDay Reporter , TUESDAY, April ... the middle ground with its new drug control policy, ... Tuesday, rejects both the harsh "war on drugs" ... the push to legalize illegal drugs. Gil Kerlikowske, ...
... HOUSTON - Scientists who developed a technology for identifying and ... have found a way to penetrate the outer membrane and ... the cell. In a paper published today online in ... The University of Texas MD Anderson Cancer Center reports packaging ...
... , TUESDAY, April 17 (HealthDay News) -- The ... apparently because of changes in the brain,s white matter, a ... aged 21 to 85, to perform a learning task involving ... that age-related declines in decision-making are associated with the weakening ...
... , TUESDAY, April 17 (HealthDay News) -- ... reduce the spread of the AIDS-causing virus, but would ... high risk for HIV infection, according to a new ... to analyze the use of the combination drug tenofovir-emtricitabine ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, April ... patients, own tumor cells led to a nearly 50 percent ... the same malignancy that claimed the life of U.S. Sen. ... multicenter trial of about 40 patients with recurrent glioblastoma -- ...
... bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell ... in 2006 did not lead to significantly increase survival ... Medicare, a new study by Dana-Farber Cancer Institute researchers has ... 18 Journal of the American Medical Association , a ...
Cached Medicine News:Health News:White House Drug Policy Shifts Strategy 2Health News:White House Drug Policy Shifts Strategy 3Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 2Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 3Health News:HIV Prevention Pill Cost-Effective for High-Risk Men: Study 2Health News:Brain Tumor Vaccine Shows Promise in Early Trial 2Health News:Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients 2
... The SkanWasher 400 is ... microplate washer with built-in ... The individual pressure settings ... very gentle wash to ...
Lab-Reader...
Fully automatic NRTL and CE certified microplate reader....
... a compact and versatile multilabel ... design allows up to six ... counting, luminescence, absorbance, and fluorescence ... and fluorescence polarization all on ...
Medicine Products: